Extracellular Vesicle‐Based mRNA Therapeutics and Vaccines
Exploration · 2025-12 · 5 (6)
DOI: 10.1002/exp.20240109 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Exploration, online erschienen am 07.08.2025. Verfasst von Qi Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science, School of Interdisciplinary Science, Aerospace Center Hospital, Key Laboratory of Molecular Medicine and Biotherapy, Key Labo…. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Messenger RNA (mRNA) therapeutics and vaccines have recently gained particular prominence following the COVID‐19 epidemic. However, clinical translation of mRNAs is critically dependent on efficient and safe delivery in vivo. Currently, a plethora of mRNA delivery technology platforms (such as lipid nanoparticles) have been developed and have achieved stunning success. Nevertheless, many challenges remain to be overcome, including immunogenicity and toxicities, excessive liver accumulation, limited endosomal escape ability, low tissue bioavailability, poor mucosal immunity, and the need for cold chain storage. In recent years, extracellular vesicles (EVs) have emerged as an attractive mRNA delivery platform due to their favorable properties, such as low immunogenicity, natural capability to deliver RNAs, intrinsic targeting capacity, and the ability to negotiate with physiological barriers. In this review, we discuss the latest efforts to harness EVs for mRNA delivery and elaborate the behind mechanisms, aiming to offering insights into the rational design of effective and safe EV‐based mRNA therapeutics and vaccines for biomedical applications. Additionally, we provide an overview of EV biogenesis, composition, cellular internalization, and their superiorities and challenges for mRNA delivery, with special emphasis on the state‐of‐the‐art methodologies for packaging EVs with mRNAs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Life Science, School of Interdisciplinary Science, Aerospace Center Hospital, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering Beiji…
- School of Medical Engineering School of Interdisciplinary Science Affiliated Zhuhai People's Hospital, Beijing Institute of Technology Zhuhai China.
- Advanced Technology Research Institute Beijing Institute of Technology Jinan China.
- Chinese Academy of Sciences (CAS) Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology of China Beijing China.
- Department of Biomedical Engineering Columbia University New York USA.
- State Key Laboratory of Toxicology and Medical Countermeasures Beijing Institute of Pharmacology and Toxicology Beijing China.
ORCID-Profile: Yuanyu Huang, Mei Lu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Zitieren
APA
Li, Q., Xing, H., Naeem, A., Zhang, K., Zheng, A., Huang, Y., & Lu, M. (2025). Extracellular Vesicle‐Based mRNA Therapeutics and Vaccines. Exploration, 5(6). https://doi.org/10.1002/exp.20240109
Vancouver
Li Q, Xing H, Naeem A, Zhang K, Zheng A, Huang Y, et al. Extracellular Vesicle‐Based mRNA Therapeutics and Vaccines. Exploration. 2025;5(6). doi:10.1002/exp.20240109
BibTeX
@article{Li2025,
author = {Li, Qi and Xing, Haonan and Naeem, Abid and Zhang, Kaiyue and Zheng, Aiping and Huang, Yuanyu and Lu, Mei},
title = {Extracellular Vesicle‐Based mRNA Therapeutics and Vaccines},
journal = {Exploration},
year = {2025},
volume = {5},
number = {6},
doi = {10.1002/exp.20240109}
}
EUVIMED